ABSTRACT
Lung cancer is a leading cause of cancer-related deaths globally, includes small cell lung cancer (SCLC), characterized by its aggressive nature and advanced disease at diagnosis. However, the identification of reliable biomarkers for SCLC has proven challenging, as no consistent predictive biomarker has been established. Nonetheless, certain tumor-associated antigens, including programmed death-ligand 1 (PDL1) and Delta-Like Ligand 3 (DLL3), show promise for targeted antibody-based immunotherapy. To ensure optimal patient selection, it remains crucial to comprehend the relationship between PDL1 and DLL3 expression and clinicopathological characteristics in SCLC. In this study, we investigated the expression patterns of PDL1 and DLL3 biomarkers in endobronchial samples from 44 SCLC patients, examining their association with clinical characteristics and survival. High PDL1 expression (>1%) was observed in 14% of patients, while the majority the SCLC patients (73%) exhibited high DLL3 expression (>75%). Notably, we found a positive correlation between high PDL1 expression (>1%) and overall survival. However, we did not observe any significant differences in the biomarkers expression concerning age, sex, disease status, smoking status, or distant metastases. Further subgroup analysis revealed that a high co-expression of both PDL1 (>1%) and DLL3 (100%) antigens was associated with improved overall survival. This suggests that SCLC expressing PDL1 and DLL3 antigens may exhibit increased sensitivity to therapy, indicating their potential as therapeutic targets. Thus, our findings provide novel insights into the simultaneous evaluation of PDL1 and DLL3 biomarkers in SCLC patients. These insights have significant clinical implications for therapeutic strategies, survival prediction, and development of combination immunotherapies.
ABSTRACT
The first case of a myxoid liposarcoma metastatic to the tongue of a 78-year-old male patient with primary scrotal liposarcoma for the past seven years is reported. The patient presented with a firm exophytic mass of the left dorsal surface of the tongue, sized 4 to 4.5 cm, with oedema and bleeding. Myxoid liposarcoma is a malignancy with relatively good prognosis and low metastatic rate but high local recurrence. This is the second case report recorded of a metastatic liposarcoma to the oral cavity. Clinical and imaging considerations, as well pathological details concerning the myxoid liposarcoma, are described.
ABSTRACT
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT) with multisystem involvement. Cases of TMA in the intestinal vasculature (intestinal TMA/iTMA) have been reported. We hypothesized that iTMA is a distinct entity from TA-TMA. To test this hypothesis, we prospectively recruited allo-HCT recipients with an indication for endoscopy. Among 20 patients, histological features of iTMA, including loss of glands, total denudation of mucosa, apoptosis and detachment of endothelial cells, mucosal hemorrhage, intraluminal fibrin and microthrombi were found in six. Only 2/6 were classified as GVHD/TA-TMA, while the other 4 as GVHD/no TA-TMA. Gastro-intestinal symptoms were similar between the patients with or without iTMA. With a median follow-up of 11.1 (2.1-67.5) months, 1-year overall survival was 22.2% for iTMA, 55% for GVHD and 60% for TA-TMA. On multivariate analysis, independent unfavorable predictors of OS were iTMA (p = 0.048), HLA mismatched donors (p = 0.008) and gastro-intestinal bleeding (p = 0.021). In conclusion, iTMA emerges as a novel distinct entity in patients with GVHD and/or TA-TMA. Distinct histological features may be useful in differential diagnosis of these severe HCT complications. The higher mortality rates of iTMA than TA-TMA highlight the need for further investigation of this condition.
Subject(s)
Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Intestinal Diseases/etiology , Thrombotic Microangiopathies/etiology , Adult , Endothelial Cells/pathology , Female , Gastrointestinal Hemorrhage/complications , Graft vs Host Disease/diagnosis , Graft vs Host Disease/mortality , Graft vs Host Disease/pathology , Humans , Intestinal Diseases/diagnosis , Intestinal Diseases/mortality , Intestinal Diseases/pathology , Male , Middle Aged , Prospective Studies , Thrombosis/etiology , Thrombotic Microangiopathies/diagnosis , Thrombotic Microangiopathies/mortality , Thrombotic Microangiopathies/pathology , Transplantation, Homologous/adverse effects , Young AdultABSTRACT
Rifampicin is a widely used anti-tuberculosis agent. Apart from hepatotoxicity, rifampicin can rarely lead to adverse reactions of immunologic nature such as acute renal failure (ARF). We report the case of 57-year-old previously healthy man under treatment for pulmonary tuberculosis who presented with hemolysis and severe ARF. Rifampicin was discontinued and the patient was treated with fluid repletion, iv furosemide and dialysis therapy. Kidney biopsy revealed acute tubulointerstitial nephritis with no evidence of granulomas. The patient significantly improved and was discharged after 51 days of hospitalization. Clinicians using rifampicin should be aware of this rather uncommon but severe complication.
Subject(s)
Acute Kidney Injury/chemically induced , Antibiotics, Antitubercular/adverse effects , Hemolysis , Rifampin/adverse effects , Tuberculosis, Pulmonary/drug therapy , Acute Kidney Injury/diagnosis , Acute Kidney Injury/therapy , Humans , Male , Middle AgedABSTRACT
Peutz-Jeghers syndrome is a rare hereditary autosomal dominant disease caused by a mutation of the tumor suppressor gene serine/threonine kinase 11 located in chromosome 19p13.3. It is characterized by the presence of extensive mucocutaneous pigmentation, especially of the lips and the occurrence of hamartomatous polyps throughout the gastrointestinal tract. Gastrointestinal hamartomas occur predominantly in the small intestine and can become symptomatic leading usually to intestinal obstruction and abdominal pain.We present a case of recurrent intestinal obstruction caused by small bowel intussusception treated by reduction, enterotomy and polypectomy and followed by intraoperative enteroscopy and endoscopic polypectomy.
Subject(s)
Intestinal Diseases/etiology , Intussusception/etiology , Peutz-Jeghers Syndrome/complications , Digestive System Surgical Procedures , Humans , Intestinal Diseases/pathology , Intestinal Diseases/surgery , Intestinal Obstruction/etiology , Intestine, Small/pathology , Intestine, Small/surgery , Intussusception/pathology , Intussusception/surgery , Laparotomy , Male , Peutz-Jeghers Syndrome/pathology , Peutz-Jeghers Syndrome/surgery , Recurrence , Young AdultABSTRACT
Peutz-Jeghers syndrome is a rare hereditary autosomal dominant disease caused by a mutation of the tumor suppressor gene serine/threonine kinase 11 located in chromosome 19p13.3. It is characterized by the presence of extensive mucocutaneous pigmentation, especially of the lips and the occurrence of hamartomatous polyps throughout the gastrointestinal tract. Gastrointestinal hamartomas occur predominantly in the small intestine and can become symptomatic leading usually to intestinal obstruction and abdominal pain. We present a case of recurrent intestinal obstruction caused by small bowel intussusception treated by reduction, enterotomy and polypectomy and followed by intraoperative enteroscopy and endoscopic polypectomy(AU)
Subject(s)
Humans , Male , Peutz-Jeghers Syndrome/complications , Peutz-Jeghers Syndrome/diagnosis , Polyps/complications , Polyps , Intestinal Polyps/complications , Abdominal Pain/etiology , Endoscopy/methods , Endoscopy , Peutz-Jeghers Syndrome/physiopathology , Peutz-Jeghers Syndrome , Hamartoma Syndrome, Multiple/complications , Hamartoma Syndrome, Multiple/diagnosisABSTRACT
Pathologic splenic rupture is defined as the spontaneous rupture of a diseased spleen and is quite rare. It is usually associated with oncologic, infectious, and hematologic diseases and more seldom with other rare causes. Pathologic splenic rupture related to hematologic malignancy seems to be rare with only 136 cases reported from 1861 until 1996 and a few cases thereafter. Non-Hodgkin lymphoma and acute myeloid leukemia are most frequently reported followed by chronic myeloid leukemia and lymphoblastic acute leukemia. However, even in cases of non-Hodgkin lymphoma, pathologic splenic rupture as the presenting symptom of the disease is rare as is the presence of primary splenic lymphoma. Conservative treatment is not an option, while operative intervention and emergency splenectomy is the only feasible treatment. We present a very rare case of pathologic rupture of primary splenic lymphoma which was the presenting symptom of the disease.
Subject(s)
Lymphoma, Non-Hodgkin/diagnosis , Splenectomy , Splenic Neoplasms/diagnosis , Splenic Rupture/diagnosis , Female , Humans , Lymphoma, Non-Hodgkin/surgery , Middle Aged , Prognosis , Splenic Neoplasms/surgery , Splenic Rupture/surgerySubject(s)
Anus Neoplasms/pathology , Carcinoma, Signet Ring Cell/pathology , Aged, 80 and over , Antimetabolites, Antineoplastic/therapeutic use , Anus Neoplasms/drug therapy , Anus Neoplasms/radiotherapy , Carcinoma, Signet Ring Cell/drug therapy , Carcinoma, Signet Ring Cell/radiotherapy , Colonoscopy , Combined Modality Therapy , Female , Fluorouracil/therapeutic use , Gastroscopy , Humans , Magnetic Resonance Imaging , PrognosisABSTRACT
Fibromyxoma represents a rare benign neoplasm that mostly affects the posterior region of the mandible. Here, we report the case of a 46-year-old male with a swelling of the right maxilla. After proper diagnosis, he was treated with enucleation and curettage of the tumor. The defect was filled with a pedicled buccal fat pad flap. The mesenchymal origin from the dental follicle of the fibromyxoma is the most plausible explanation. Radiological examination with MRI, CT, and conventional radiography contributes to the differential diagnosis from other benign tumors, such as the ameloblastoma. Its management is surgical and comprises enucleation and curettage or en bloc resection. Patients must be monitored for at least two years postoperatively in order to diagnose possible recurrence. According to the literature, the maxilla is a rare location of a fibromyxoma and, to our knowledge, our case is the 30th presented case of a fibromyxoma of the maxilla.
ABSTRACT
Adrenal myelolipoma is an uncommon, benign, biochemically non-functioning and endocrinologically inactive tumor composed of variable amounts of mature adipose tissue and scattered islands of haemopoietic elements, including erythroid, myeloid and lymphoid series, as well as megakaryocytes. Diagnosis of myelolipomas is based on imaging, with ultrasonography, CT and MRI being effective in more than 90% of cases. Differential diagnosis includes other containing fat adrenal masses such as teratoma, lipoma and liposarcoma. The optimal treatment depends on the size and symptoms of the myelolipoma. For incidentally discovered, asymptomatic adrenal myelolipomas smaller than 4 cm surveillance seems to be enough while symptomatic, complicated, hormonally active and larger than 7 cm myelolipomas, should be surgically removed. We present a case of giant bilateral symptomatic adrenal myelolipomas associated with congenital adrenal hyperplasia. A 34 year old female, with congenital adrenal hyperplasia because of 21-hydroxylase deficiency, presented with diffuse abdominal pain and vomiting. Physical examination revealed hirsutism, pronounced virilization and palpable masses both on the right and left abdominal area. The abdominal CT demonstrated bilateral large masses in the anatomical position of the adrenal glands with densities indicating adipose tissue. The differential diagnosis was between myelolipoma and liposarcoma. For diagnostic and also therapeutical reasons, as the masses were large and symptomatic and causing pressure to the surrounding structures, the patient was submitted to laparotomy for bilateral excision. Histopathological examination established the diagnosis of adrenal myelolipoma.